Heng Liang

6.1k total citations · 5 hit papers
28 papers, 4.9k citations indexed

About

Heng Liang is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, Heng Liang has authored 28 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 10 papers in Immunology and 8 papers in Cancer Research. Recurrent topics in Heng Liang's work include RNA modifications and cancer (7 papers), Cancer-related molecular mechanisms research (5 papers) and RNA and protein synthesis mechanisms (4 papers). Heng Liang is often cited by papers focused on RNA modifications and cancer (7 papers), Cancer-related molecular mechanisms research (5 papers) and RNA and protein synthesis mechanisms (4 papers). Heng Liang collaborates with scholars based in United States, China and Canada. Heng Liang's co-authors include Stephen W. Fesik, Craig B. Thompson, Robert Meadows, David G. Nettesheim, Ho Sup Yoon, Michael Sattler, Brian S. Chang, John E. Harlan, Andy J. Minn and Steven W. Muchmore and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Heng Liang

27 papers receiving 4.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structure of Bcl-x _L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis

1997 1.2k citations Michael Sattler, Heng Liang et al. profile →
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

1996 1.2k citations Steven W. Muchmore, Michael Sattler et al. Nature profile →
Bcl-xL forms an ion channel in synthetic lipid membranes

1997 682 citations Heng Liang, Steven W. Muchmore et al. Nature profile →
RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3

2019 455 citations Yi Niu, Ziyou Lin et al. Molecular Cancer profile →
RNA m ⁶ A methylation regulates sorafenib resistance in liver cancer through FOXO 3‐mediated autophagy

2020 359 citations Ziyou Lin, Yi Niu et al. The EMBO Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heng Liang United States	18	4.3k	838	768	700	390	28	4.9k
Erinna F. Lee Australia	37	4.4k 1.0×	429 0.5×	948 1.2×	1.1k 1.6×	616 1.6×	73	5.5k
Martin Renatus United States	26	3.5k 0.8×	599 0.7×	748 1.0×	720 1.0×	628 1.6×	39	4.6k
Yuan Chen United States	36	3.8k 0.9×	679 0.8×	528 0.7×	1.1k 1.6×	286 0.7×	121	4.7k
Celia R. Berkers Netherlands	31	3.9k 0.9×	1.2k 1.4×	714 0.9×	1.4k 2.0×	476 1.2×	76	5.3k
Evripidis Gavathiotis United States	38	4.5k 1.0×	414 0.5×	596 0.8×	780 1.1×	787 2.0×	75	5.8k
Dayong Zhai United States	36	3.0k 0.7×	336 0.4×	751 1.0×	667 1.0×	386 1.0×	80	4.2k
Catherine L. Day New Zealand	38	6.1k 1.4×	745 0.9×	1.2k 1.6×	1.8k 2.5×	667 1.7×	81	7.4k
Andrew M. Petros United States	32	3.4k 0.8×	328 0.4×	454 0.6×	659 0.9×	334 0.9×	60	4.4k
Chaohong Sun United States	24	2.8k 0.7×	245 0.3×	399 0.5×	524 0.7×	373 1.0×	46	3.6k

Countries citing papers authored by Heng Liang

Since Specialization

Citations

This map shows the geographic impact of Heng Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heng Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heng Liang more than expected).

Fields of papers citing papers by Heng Liang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heng Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heng Liang. The network helps show where Heng Liang may publish in the future.

Co-authorship network of co-authors of Heng Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Heng Liang. A scholar is included among the top collaborators of Heng Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heng Liang. Heng Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Yunqiu, Jinhua Zhan, Heng Liang, et al.. (2025). IDO1 inhibitors block septic cytokine storm by suppressing the IDO1-AHR-CYP1A1 axis. Biomedicine & Pharmacotherapy. 187. 118054–118054.

Liu, Chuwei, Heng Liang, Arabella Wan, et al.. (2025). Decoding the m6A epitranscriptomic landscape for biotechnological applications using a direct RNA sequencing approach. Nature Communications. 16(1). 798–798. 9 indexed citations

Xing, Zikang, Xuewen Li, Xin Fang, et al.. (2024). IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma. Pharmaceutics. 16(7). 870–870. 9 indexed citations

Liu, Moyang, et al.. (2024). Polyploidy drives autophagy to participate in plant‐specific functions. SHILAP Revista de lepidopterología. 3(6). e252–e252. 4 indexed citations

Li, Qiaoxi, et al.. (2024). Physiologically Based Pharmacokinetic Modeling of Vancomycin and its Comparison with Population Pharmacokinetic Model in Neonates. The Journal of Clinical Pharmacology. 65(1). 87–95. 1 indexed citations

He, Zhichao, et al.. (2023). A high-throughput UHPLC-MS/MS method for the determination of eight anti-tumor drugs in plasma. Analytical Biochemistry. 676. 115230–115230. 5 indexed citations

Sun, Lei, Zhengyu Liu, Arabella Wan, et al.. (2023). Galectin-7 Induction by EHMT2 Inhibition Enhances Immunity in Microsatellite Stability Colorectal Cancer. Gastroenterology. 166(3). 466–482. 16 indexed citations

Chen, Xi, Wen Xie, Heng Liang, et al.. (2022). FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 28(17). 3770–3784. 32 indexed citations

Lin, Ziyou, Arabella Wan, Lei Sun, et al.. (2022). N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis. Molecular Therapy. 31(2). 517–534. 56 indexed citations

10.

Chen, Xi, Guohui Wan, Heng Liang, et al.. (2022). FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy. Acta Pharmaceutica Sinica B. 12(9). 3639–3649. 8 indexed citations

11.

Deng, Yuan, Arabella Wan, Jiarui Li, et al.. (2022). RNA and RNA Derivatives: Light and Dark Sides in Cancer Immunotherapy. Antioxidants and Redox Signaling. 37(16-18). 1266–1290. 1 indexed citations

12.

Niu, Yi, Ziyou Lin, Arabella Wan, et al.. (2021). Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia. Hepatology. 74(3). 1461–1479. 91 indexed citations

13.

Deng, Yuan, Lei Sun, Heng Liang, et al.. (2021). Measurement of Circulating Tumor Cells to Track Hepatocellular Carcinoma Progression After Liver Transplantation-Case Report. Frontiers in Oncology. 11. 760765–760765. 3 indexed citations

14.

Lin, Ziyou, Yi Niu, Arabella Wan, et al.. (2020). RNA m ⁶ A methylation regulates sorafenib resistance in liver cancer through FOXO 3‐mediated autophagy. The EMBO Journal. 39(12). e103181–e103181. 359 indexed citations breakdown →

15.

Sun, Lei, Arabella Wan, Zhuolong Zhou, et al.. (2020). RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer. Gut. 70(9). 1698–1712. 86 indexed citations

16.

Niu, Yi, Ziyou Lin, Arabella Wan, et al.. (2019). RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Molecular Cancer. 18(1). 46–46. 455 indexed citations breakdown →

17.

Liu, Gang, Bruce G. Szczepankiewicz, Zhonghua Pei, et al.. (2003). Discovery and Structure−Activity Relationship of Oxalylarylaminobenzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B. Journal of Medicinal Chemistry. 46(11). 2093–2103. 51 indexed citations

18.

Muchmore, Steven W., Michael Sattler, Heng Liang, et al.. (1996). X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature. 381(6580). 335–341. 1199 indexed citations breakdown →

19.

Liang, Heng, Xiaohong Mao, Edward T. Olejniczak, et al.. (1994). Solution structure of the ets domain of Fli-1 when bound to DNA. Nature Structural & Molecular Biology. 1(12). 871–876. 90 indexed citations

20.

Liang, Heng & Thomas C. Terwilliger. (1991). Reversible denaturation of the gene V protein of bacteriophage f1. Biochemistry. 30(11). 2772–2782. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact